PENUMBRA INC (PEN) Stock Price & Overview
NYSE:PEN • US70975L1070
Current stock price
The current stock price of PEN is 337.36 USD. Today PEN is down by 0%. In the past month the price decreased by -0.98%. In the past year, price increased by 20.32%.
PEN Key Statistics
- Market Cap
- 13.238B
- P/E
- 87.85
- Fwd P/E
- 65.96
- EPS (TTM)
- 3.84
- Dividend Yield
- N/A
PEN Stock Performance
PEN Stock Chart
PEN Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to PEN. When comparing the yearly performance of all stocks, PEN is one of the better performing stocks in the market, outperforming 76.84% of all stocks.
PEN Fundamental Analysis
ChartMill assigns a fundamental rating of 7 / 10 to PEN. PEN has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company.
PEN Earnings
On February 25, 2026 PEN reported an EPS of 1.18 and a revenue of 385.38M. The company beat EPS expectations (5.02% surprise) and beat revenue expectations (4.03% surprise).
PEN Forecast & Estimates
23 analysts have analysed PEN and the average price target is 365.95 USD. This implies a price increase of 8.48% is expected in the next year compared to the current price of 337.36.
For the next year, analysts expect an EPS growth of 33.19% and a revenue growth 14.66% for PEN
PEN Groups
Sector & Classification
PEN Financial Highlights
Over the last trailing twelve months PEN reported a non-GAAP Earnings per Share(EPS) of 3.84. The EPS increased by 33.8% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 12.66% | ||
| ROA | 9.73% | ||
| ROE | 12.45% | ||
| Debt/Equity | 0.01 |
PEN Ownership
PEN Latest News, Press Relases and Analysis
PEN Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 18.49 | 186.262B | ||
| ISRG | INTUITIVE SURGICAL INC | 46.76 | 170.438B | ||
| SYK | STRYKER CORP | 22.26 | 130.023B | ||
| BSX | BOSTON SCIENTIFIC CORP | 19.98 | 103.709B | ||
| EW | EDWARDS LIFESCIENCES CORP | 27.23 | 47.893B | ||
| IDXX | IDEXX LABORATORIES INC | 38.96 | 46.168B | ||
| BDX | BECTON DICKINSON AND CO | 11.45 | 44.57B | ||
| RMD | RESMED INC | 18.39 | 33.129B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 13.52 | 32.076B | ||
| DXCM | DEXCOM INC | 26.41 | 25.89B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 10.41 | 17.577B | ||
| HOLX | HOLOGIC INC | 15.38 | 16.817B | ||
| PODD | INSULET CORP | 35.27 | 16.096B |
Related stock screener links
View all stocks in the Health Care Equipment Industry | View all stocks in the Health Care Sector | View all stocks on the New York Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About PEN
Company Profile
Penumbra, Inc. is a thrombectomy company, which designs, develops, manufactures, and markets innovative medical products. The company is headquartered in Alameda, California and currently employs 4,700 full-time employees. The company went IPO on 2015-09-18. The firm's broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe. The company focuses on developing, manufacturing and marketing novel products for use by specialist physicians and healthcare providers to drive improved clinical and health outcomes. Some of the conditions it focuses on are Pulmonary Embolism, Deep Vein Thrombosis, Acute Limb Ischemia, Ischemic Stroke, Acute Coronary Syndrome, and Clot associated with Arteriovenous Graft or Fistula. The firm sells its products to healthcare providers primarily through its direct sales organization in the United States, Europe, Canada and Australia, as well as through distributors in select international markets.
Company Info
IPO: 2015-09-18
PENUMBRA INC
One Penumbra Place
Alameda CALIFORNIA 94502 US
CEO: Adam Elsesser
Employees: 4700
Phone: 13025310855
PENUMBRA INC / PEN FAQ
What does PENUMBRA INC do?
Penumbra, Inc. is a thrombectomy company, which designs, develops, manufactures, and markets innovative medical products. The company is headquartered in Alameda, California and currently employs 4,700 full-time employees. The company went IPO on 2015-09-18. The firm's broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe. The company focuses on developing, manufacturing and marketing novel products for use by specialist physicians and healthcare providers to drive improved clinical and health outcomes. Some of the conditions it focuses on are Pulmonary Embolism, Deep Vein Thrombosis, Acute Limb Ischemia, Ischemic Stroke, Acute Coronary Syndrome, and Clot associated with Arteriovenous Graft or Fistula. The firm sells its products to healthcare providers primarily through its direct sales organization in the United States, Europe, Canada and Australia, as well as through distributors in select international markets.
What is the stock price of PENUMBRA INC today?
The current stock price of PEN is 337.36 USD.
What is the dividend status of PENUMBRA INC?
PEN does not pay a dividend.
How is the ChartMill rating for PENUMBRA INC?
PEN has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 7 out of 10.
Is PENUMBRA INC (PEN) expected to grow?
The Revenue of PENUMBRA INC (PEN) is expected to grow by 14.66% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
How many employees does PENUMBRA INC have?
PENUMBRA INC (PEN) currently has 4700 employees.